This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2023 Jan 1;183(1):84.

doi: 10.1001/jamainternmed.2022.5418.

Savings Associated With "Skinny Label" Biosimilars

Eric Ward^{1

2}, Robert Steinbrook³

Affiliations

Affiliations

¹ Department of Medicine, University of California, San Francisco.
² Editorial Fellow, JAMA Internal Medicine.
³ Editor at Large and Online Editor, JAMA Internal Medicine.

PMID: 36441538
DOI: 10.1001/jamainternmed.2022.5418

Editorial

Savings Associated With "Skinny Label" Biosimilars

Eric Ward et al. JAMA Intern Med. 2023.

. 2023 Jan 1;183(1):84.

doi: 10.1001/jamainternmed.2022.5418.

Authors

Eric Ward^{1

2}, Robert Steinbrook³

Affiliations

¹ Department of Medicine, University of California, San Francisco.
² Editorial Fellow, JAMA Internal Medicine.
³ Editor at Large and Online Editor, JAMA Internal Medicine.

PMID: 36441538
DOI: 10.1001/jamainternmed.2022.5418

No abstract available

PubMed Disclaimer

Comment on

Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings.
Egilman AC, Van de Wiele VL, Rome BN, Darrow JJ, Tu SS, Kesselheim AS, Sarpatwari A. Egilman AC, et al. JAMA Intern Med. 2023 Jan 1;183(1):82-84. doi: 10.1001/jamainternmed.2022.5419. JAMA Intern Med. 2023. PMID: 36441536 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems